BioCryst Pharmaceuticals Inc. (BCRX)
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2024 Earnings Call Transcript August 5, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Chris Raymond - Piper Sandler Gena Wang - Barclays Maury Raycroft - Jefferies Stacy Ku - TD Cowen Jon Wolleben - JMP Securities Serge Belanger - Needham & Company Operator Good day and welcome to the BioCryst Second Quarter 2024 Earnings Call. All participants will be in listen-only mode.
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
BioCryst Pharmaceuticals develops complement-mediated and rare disease treatments using a structure-guided drug design process. The company's pipeline also includes promising drug candidates in pivotal phases and pre-clinical stages. The company relies heavily on Orladeyo, which represents 95.8% of its total revenues.
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 92.6% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
